2Chapman PT, Yarwood H, Harrison AA, et al. Endothelial activation in mono sodium uratemonohydrate crystal-in duced inflammation : in vivo and vitro studies on the roles of TN F-A and IL-1. Arthritis Rheum, 1997,40: 955.
3McCarty FN, Allen JB, Mizel DI, et al. Superssion of Afithfitis by an in- hibiter of itricoxidesynthase. JEXP Me, 1993,1178:74.
5Becker MA, Schumacher HRJ, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med, 2005,353:2450.
6Khosravan R, Grabowski BA, Mayer MD, et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpufine selective inhibitor of xanthine oxidase. J Clin Pharmacol,2006,46:88.
7Horiuchi H, Ota M, Nishimura SI, et al. AUopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Sci ,2000,66:2051.
5Khanna D, Khanna P P, Fitzgerald J D, et al.2012 American College of Rheumatology guidelines for management of gout. Part 2 : therapy and antiinflammatory prophylaxis of acute gouty arthritis[J]. Arthritis Care Res ( Hoboken ), 2012, 64 ( 10 ) : 1447-1461.
6TMOTHY A, HELEN Z. Substituted thiazoles : US, 20050027128[P]. 2005 - 03 - 03.
7ROBBINS, TIMOTHY A. Process for preparing substituted thia- zoles : US ,20050075503 [ P]. 2005 - 04 - 07.
